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Abstract Lymphatic vessels play important roles in the
pathogenesis of many conditions that have an increased
prevalence in the elderly population. However, the effects
of the aging process on the lymphatic system are still rel-
atively unknown. We have applied non-invasive imaging
and whole-mount staining techniques to assess the lym-
phatic vessel function and morphology in three different
age groups of mice: 2 months (young), 7 months (middle-
aged), and 18 months (aged). We first developed and val-
idated a new method to quantify lymphatic clearance from
mouse ear skin, using a lymphatic-specific near-infrared
tracer. Using this method, we found that there is a promi-
nent decrease in lymphatic vessel function during aging
since the lymphatic clearance was significantly delayed in
aged mice. This loss of function correlated with a
decreased lymphatic vessel density and a reduced lym-
phatic network complexity in the skin of aged mice as
compared to younger controls. The blood vascular leakage
in the skin was slightly increased in the aged mice, indi-
cating that the decreased lymphatic function was not
caused by a reduced capillary filtration in aged skin. The
decreased function of lymphatic vessels with aging might
have implications for the pathogenesis of a number of
aging-related diseases.
Keywords Aging  Lymphatic vessels  Vascular
leakage  In vivo imaging
Introduction
The lymphatic vascular system is responsible for the
maintenance of tissue fluid homeostasis, the migration of
immune cells to secondary lymphatic organs and the
uptake of dietary fat from the intestine [1]. The lymphatic
vasculature is also critical in pathological situations such as
the spread of cancer cells from solid tumors, the develop-
ment of lymphedema, and the resolution of chronic
inflammation [2]. Recently, it has been discovered that
lymphatic vessels in the skin also play key roles in reverse
cholesterol transport [3, 4] and salt uptake for blood pres-
sure regulation [5], findings that may have clinical impli-
cations for heart disease.
Despite the increased prevalence of lymphatic-related
diseases with age, our knowledge about how the lymphatic
system is affected by the aging process is still limited.
Previous studies have suggested that lymphatic function
might decline with age [6]. Two studies used lym-
phoscintigraphy in elderly patients with cancer and venous
disease and found a decreased nodal uptake of lym-
phoscintigraphic tracers in aged individuals [7, 8]. More
recent reports indicate that collecting lymphatic vessels in
aged rats have a reduced pumping efficiency [9–11]. A
recent clinical study supported this finding, using a pres-
sure cuff technique and near-infrared (NIR) imaging with
indocyanine green dye to find a reduced pumping strength
of collecting lymphatic vessels in the leg of aged individ-
uals [12]. However, a study combining functional and
morphological data to evaluate the effect of aging on
dermal lymphatic vessels has not yet been performed.
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In order to assess how lymphatic function is altered
during aging, new methods are needed that can accurately
quantify the function of the lymphatic vascular system in a
non-invasive manner. A clinical method that can track
lymphatic removal of an interstitial depot of radiolabeled
tracer was developed for assessment of the lymphatic
function in patients with lymphedema [13]. This approach
was adapted for use in rodent models using a fluorescent
dye bound to human albumin [14]. We have recently
developed polyethylene glycol (PEG)-conjugated NIR
fluorescent tracers of sufficient molecular weight such that
they are specifically taken up by the lymphatic vessels after
intradermal injection with no uptake visualized in the
venous system [15]. The fluorescent dye remains stably
bound to the PEG molecule in vivo and the tracers do not
demonstrate accumulation in the draining lymph nodes
through phagocytosis [2]. Therefore, these tracers have
great potential to quantify lymphatic clearance by moni-
toring the disappearance of fluorescent signal at the site of
injection.
In the current study, we established and validated a new
assay for measuring lymphatic clearance from mouse skin.
Using this assay, we demonstrated that there is a steady
decline in the lymphatic clearance rate with age. This
decline is associated with a reduction in lymphatic vascular
density and complexity in the skin.
Methods
Mice
C57BL/6 J-Tyrc-J albino mice (Jackson Laboratories) and
C57BL/6C mice (Charles River) were maintained under
pathogen-free conditions until imaging. K14-VEGF-C and
K14-sVEGFR-3-Fc mice on an FVB background were a
kind gift of Dr. Kari Alitalo, University of Helsinki [16,
17]. After imaging, the mice were euthanized with an
overdose of anesthesia (1000 mg/kg ketamine; 3.5 mg/kg
medetomidine) followed by cervical dislocation. All
methods were carried out in strict accordance with the
approved guidelines and all experiments were performed in
accordance with animal protocols approved by Kantonales
Veterinaramt Zurich (protocol: 237/2013).
Lymphatic-specific imaging tracers
The PEG-based lymphatic tracer P20D800 was prepared by
reacting methoxypoly(ethylene glycol) amine P20 (20 kDa)
equimolarly with IRDye 800CW NHS Ester (LI-COR
Biosciences, Lincoln, NE) in anhydrous dimethyl sulphox-
ide. The crude reaction was then diluted with 4 mL of
ultrapure water and freeze-dried overnight to ensure
complete removal of the organic solvent. The dry lyophili-
zate was then reconstituted with 250 lL of HEPES buffered
saline (20 mmol/L HEPES, 145 mmol/L NaCl, pH 7.4) and
purified, as previously described [18]. The stock solutions of
the polymeric dyes were kept at -20 C until further use.
Stability of P20D800 in lymph
In order to check the stability of the tracer in lymph, a
P20D800 stock solution in HEPES buffered saline was
incubated at 37 C for 24 h (7.5 lmol/L D800 concentra-
tion in lymph) under constant shaking. At allotted time
points aliquots were collected, deproteinized, and analyzed
via HPLC.
Deproteinization of P20D800-containing lymph was
achieved following an optimized method that allowed
100 % dye recovery from lymph [19]. Briefly, a volume of
20 lL of dye-containing lymph was added to 30 lL of
acetonitrile/methanol (47/3 v/v). The tube was vortexed
and centrifuged for 10 min at 15009g. The supernatant
was withdrawn, and eluted in an analytical HPLC follow-
ing the gradient protocol (% A/B): 90/10 to 50/50 for
10 min, isocratic 50/50 for 5 min, 50/50 to 10/90 for
10 min, isocratic 10/90 for 5 min, 10/90 to 90/10 for
5 min, where solvent A consisted of 10 mmol/L tetra-
butylammonium bromide (Sigma) aqueous solution and
solvent B of 10 mmol/L tetrabutylammonium bromide in
acetonitrile/water (90/10 v/v). The flow rate of the mobile
phase was 1.0 mL/min. The detector wavelength was set at
780 nm. The chromatographic column used was a YMC
Pack Pro C18 150 mm 9 4.6 mm column with 3 lm
particles (YMC Co., Kyoto, Japan). Pure D800 carboxylate
dye diluted in acetonitrile/methanol (47/3 v/v) was also
eluted (7.5 lmol/L D800 concentration in lymph) as con-
trol. The retention times for D800 and P20D800 were 19.3
and 13.9 min, respectively.
Lymphatic clearance assay
Lymphatic vessel drainage function was assessed by
measuring the clearance over time after intradermal skin
injection of P20D800. Mice were anesthetized with
isoflurane (2 %), and 3 lL of 3 lmol/L P20D800 was
injected into the ears with a 29-G insulin syringe (Teramu,
Somerset, NJ). The mice were then positioned in an IVIS
spectrum (Caliper Life Sciences, Hopkington, MA) and an
image was acquired with the following imaging settings:
kex: 745 nm, kem: 800 nm, binning of 2. An exposure time
of 2 s was used for imaging in albino mouse strains, with
an increased exposure time of 4 s for black mouse strains
due to higher absorption from pigmentation and black fur.
Subsequent images were acquired of the ears at 1, 2, 3, 4, 6,
and 24 h after injection. Mice were allowed to wake up and
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move freely between imaging time points. Fluorescence
signal intensities were adjusted to baseline ear signals
before injection of tracers to calculate tissue enhancement
values. Since there may be slight variations in the amount
of tracer injected and in the initial distribution of the tracer
after injection, we normalized the tissue enhancement
values using a region of interest (ROI) encompassing the
entire ear at all time points to the value directly after
injection. The normalized fluorescence intensity values
over time were fit to a one-phase exponential decay model
in GraphPad Prism software with lymphatic clearance
expressed as decay constant k (expressed in h-1) or as half-
life (expressed in h) using the following equations:
Normalized Fluorescence Intensity ¼ ekt; ð1Þ
Half Life ¼ ln(2)=k: ð2Þ
For mice in which both ears were injected, values from
each ear were averaged together to generate one decay
constant k and half-life value per mouse.
Evans blue lymphatic clearance assay
Quantification of residual Evans blue dye in tissue after
intradermal injection was performed as previously descri-
bed [20]. Briefly, 3 lL of 1 % Evans blue dye (Sigma) was
injected into the ear skin of isoflurane anesthetized mice.
After 24 h, the mice were sacrificed and the Evans blue dye
was extracted from the tissue by incubation of the ears in
formamide (Fluka). Absorbance was measured using an
Infinite M200 microplate reader (Tecan, Männedorf, Ger-
many) by measuring at 620 nm. The concentration of dye
in the tissue was calculated using a standard curve of Evans
blue in formamide. Absorbance for P20D800 could not be
detected using the microplate reader at 620 nm.
Ear lymphangiography
High-resolution functional imaging to assess the spread of
tracer within the dermal lymphatic network of the ear was
performed after 3 lL of 20 lM P20D800 was injected
using a 29-G insulin syringe (Teramu). Images at 200 ms
exposure were acquired immediately after injection using a
Zeiss StereoLumar microscope with AxioVision (Zeiss)
software and a cooled EMCCD camera (Evolve eXcelon,
Photometrics, Tuscon, AZ), light emitting diode (LED)
system with illumination at 770 nm (CoolLED, Andover,
UK) and specific filters for ICG (Semrock, Rochester, NY).
Vascular leakage assay
Vascular leakage was imaged and quantified as previously
described [18]. In summary, vascular leakage was measured
by dynamic imaging using an IVIS Spectrum in anesthetized
C57BL/6 J-Tyrc-J albino female mice (n = 6 young and
n = 5 aged). A sequence of 3 s exposure images (excitation
745 nm, emission 800 nm, binning of 4) was initiated and
paused after the first image was acquired. Then, 100 lL per
20 g mouse weight of 10 lmol/L P20-D800 tracer was
injected intravenously into the tail vein and the imaging
sequence was immediately resumed. Images were acquired
every 15 s for a total imaging time of 15 min. ROIs were
drawn on each ear and the saphenous vein and the signal
intensity values at each time point were determined using
Living Image 4.0 software (Caliper). Leakage rates were
determined by normalizing the signal intensity values of the
ear ROIs to the value of the saphenous vein ROI at each time
point to adjust for injected dose and the dynamics of
intravascular signal. Blood volume fractions, tissue leakage
rates, and vascular leakage rates were calculated as previ-
ously described [18].
Whole mount immunostainings
Whole mount immunostainings were performed as descri-
bed [21]. Briefly, right ears were split in half and the inner
part of the ear (without cartilage) was used for analyses.
Lymphatic vessels were visualized using a rabbit-anti-
mouse LYVE-1 (AngioBio, Cat no: 11-034, 1:600 dilution)
as primary antibody. Alexa647 conjugated secondary
antibody was purchased from Molecular Probes (Cat no:
A-31573, 1:200 dilution). Thereafter, the samples were
flat-mounted on glass slides using Mowiol (Calbiochem).
Wide-field images of the whole ears at 69 and of a 349
region of interest close to the rim of the ear were obtained
with a Zeiss StereoLumar microscope at 200 ms exposure
with the Cy5 filter set. The acquired images were processed
using Adobe Photoshop CS5 (Adobe Systems) and the
LYVE-1 ? area was analyzed with a self-prepared pipe-
line in CellProfiler software (version 2.1.0, BROAD
Institute). Vessel length was measured in ImageJ (NIH) as
described [22] and the number of branch points was
counted manually.
Statistical methods
All data are shown as mean ± SD. Means of two groups
were compared using two-tailed Student’s t test; Welch’s
correction was used in case of unequal variances. Means
of three groups were compared with one-way ANOVA
with Tukey’s multiple comparison post hoc test. All
analyses were performed using GraphPad Prism V5.0
(GraphPad Software, San Diego, CA) or SPSS Statistics
version 22 (IBM) and P\ 0.05 was accepted as statis-
tically significant.
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Results
Establishment and validation of a lymphatic
clearance assay in mouse skin using NIR imaging
tracers
We first aimed to establish an in vivo lymphatic clearance
assay using the NIR tracer P20D800 [18]. This tracer is
comprised of the NIR dye IRDye800 bound to 20 kDa PEG
for an effective hydrodynamic diameter of about 8.4 nm.
We have previously shown specific uptake of the tracer by
lymphatic vessels after interstitial injection [15]. P20D800
is stable in lymph as evidenced by the absence of cleavage
of the fluorophore IRDye800 from the PEG polymer upon
24 h incubation at 37 C (data not shown) and it is excreted
intact by the kidneys after intravenous administration [18].
After interstitial injection, the removal rate of macro-
molecules by the lymphatic system has been found to follow
a one-phase exponential decay model [13, 14]. With nor-
malization of the fluorescence intensity in the tissue to the
level directly after injection and the assumption that the
signal will eventually decay to baseline fluorescence values,
we hypothesized that the signal over a series of measure-
ments should follow the model shown in Fig. 1a. For this
model to be valid, however, the lymphatic tracer concen-
tration should exhibit a linear relationship with fluorescence
intensity. We therefore tested a dilution series of concen-
trations by using fluorescence measurements in an IVIS
Spectrum imaging system and demonstrated a direct linear
relationship (linear regression r2 = 0.9958, P\ 0.0001) of
fluorescence intensity with concentrations up to 3 lM
(Fig. 1b). We therefore chose to inject a concentration of
3 lM P20D800 for monitoring lymphatic clearance out of
skin over time.
We next compared P20D800 clearance from the skin with
the established Evans Blue assay, in which lymphatic func-
tion is estimated from the amount of residual injected dye in
skin after a period of time by extracting the dye from the
tissue of sacrificed animals [20].We performedboth assays in
normal mice and in K14-VEGF-C transgenic mice that
overexpress the lymphangiogenic growth factor VEGF-C in
the skin [16] and that have previously been shown to have
increased lymphatic function with the Evans Blue assay [20].
We injected 3 lL of 1 % Evans Blue dye into the skin of the
left ear and 3 lL of 3 lM P20D800 into the right ear of
7-month-old male K14-VEGF-C transgenic mice and FVB
wildtype littermates (Fig. 1c). Imaging in an IVIS spectrum
revealed that immediately after injection of Evans Blue and
P20D800, both tracers spread throughout the ear tissue of
K14-VEGF-C mice whereas the tracer was more localized in
wildtype mice (Fig. 1d). We confirmed with high-resolution
stereomicroscopy that the network of lymphatic vessels is
vastly expanded in whole mounts of the skin of these mice as
compared to wildtype mice and that after injection the tracer
quickly spreads within the dermal lymphatic vessels in K14-
VEGF-C mice, as previously described [18, 23, 24] (Sup-
plementary Fig. 1a, b online). By sequential IVIS imaging of
a region of interest encompassing the entire ear, the loss of
P20D800 fluorescence from the right ear was apparent using
the NIR tracers, with enhanced disappearance in the K14-
VEGF-C mice (Fig. 1d, e). The fluorescence decay fit very
closely to the one-phase exponential decay model, with a
mean r2 value of 0.987 ± 0.012 for the six animals studied.
Quantification using the one-phase exponential decay model
confirmed the significantly increased clearance in K14-
VEGF-C mice, as expressed by a reduced tissue half-life
(wildtype = 3.2 ± 0.2 h; K14-VEGF-C = 2.2 ± 0.1 h;
P = 0.003; Fig. 1f) and an increased clearance rate (wild-
type = 0.22 ± 0.02 h-1; K14-VEGF-C = 0.32 ± 0.02 h-1;
P = 0.002; Fig. 1g). Quantification of the Evans Blue dye
extracted from the ears only revealed a non-significant trend
towards increased clearance in the K14-VEGF-C mice
(wildtype = 8.6 ± 4.3 lg/mL; K14-VEGF-C = 4.4 ± 1.1
lg/mL; P = 0.177; Fig. 1h).
We next applied the NIR clearance assay to a model of
diminished lymphatic function, namely the K14-sVEGFR-3-
Fc transgenicmice, which lack dermal lymphatic vessels [17,
25]. Injections of P20D800 were performed into both ears of
7-month-old male K14-sVEGFR-3-Fc mice (n = 6) and
wildtype littermates (n = 5). Tracking and quantification of
the fluorescent signal, using the IVIS Spectrum, revealed that
more tracer remained in the ears of K14-sVEGFR-3-Fc mice
compared to wildtype controls (Supplementary Fig. 2a, b
online). The decreased lymphatic function in the K14-
sVEGFR-3-Fcmicewas reflected by a significantly increased
half-life (wildtype = 4.0 ± 0.3 h; K14-sVEGFR-3-Fc =
11.9 ± 3.1 h; P = 0.002; Supplementary Fig. 2c online)
and significantly reduced clearance rate (wildtype =
0.17 ± 0.01 h-1; K14-sVEGFR-3-Fc = 0.06 ± 0.02 h-1;
P\ 0.001; Supplementary Fig. 2d online). After injection of
5 lL of 3 lM P20D800 into the paw skin of K14-sVEGFR-
3-Fc (n = 4) and wildtype littermates (n = 3), we again
found a significant increase in tracer half-lives in the K14-
sVEGFR-3-Fc mice (wildtype = 2.4 ± 0.6 h; K14-
sVEGFR-3-Fc = 13.5 ± 3.4 h; P = 0.003) with a corre-
sponding decrease in the clearance rate (wildtype =
0.31 ± 0.09 h-1; K14-sVEGFR-3-Fc = 0.06 ± 0.02 h-1;
P = 0.043; Supplementary Fig. 3 online).
Reduction of lymphatic clearance during aging
We next applied the lymphatic clearance assay to investi-
gate lymphatic function during aging. Three groups of
female C57BL/6C mice were analyzed: young (2-months
492 Angiogenesis (2015) 18:489–498
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old, n = 10), middle-aged (7-months old, n = 10) and
aged (18-months old, n = 7). P20D800 was injected into
each ear and the fluorescence was tracked over time
(Fig. 2a). A clear difference could be seen with an
increased amount of dye remaining in the skin of aged mice
compared to the middle-aged and young mice. The tracer
half-life (Fig. 2b) in aged mice (3.44 ± 0.87 h) was sig-
nificantly longer than in middle-aged (2.7 ± 0.5 h;
P = 0.017) and young mice (2.1 ± 0.4 h; P\ 0.001). The
clearance rate (Fig. 2b) was significantly reduced in aged
mice (0.22 ± 0.05 h-1) when compared to young mice
(0.34 ± 0.06 h-1; P\ 0.001).
This experimentwas repeatedwith femalemice of the same
age groups in the C57BL/6 J-Tyrc-J albino strain with similar
findings (half-lives: young = 1.6 ± 0.3 h, middle-aged =
2.2 ± 0.6 h, aged = 2.7 ± 0.4 h; P\0.01 between young
Fig. 1 Establishment of a clearance assay for lymphatic function in
mouse skin. a The loss of fluorescence signal after injection of
lymphatic specific fluorescent tracer should exhibit a one-phase
exponential decay curve over time. Equations for the lymphatic
clearance rate k and the half-life of clearance can be solved by
plotting the normalized fluorescence (NF) intensity at several time
points after injection (eg. 0, 1, 2, 4, 6, and 24 h). b Demonstration of
the linear relationship between signal intensity and concentration of
P20D800 as measured using an IVIS Spectrum. c Experimental setup
to compare 1 % Evans Blue versus P20D800 tracers for
measurements of lymphatic clearance. d Representative images from
sequential imaging of wildtype and K14-VEGF-C mice after injection
of Evans Blue in the left ear and P20D800 into the right ear.
e Normalized fluorescence intensity over time for wildtype and K14-
VEGF-C mice (n = 3 each). Quantification of tracer half-lives (f) and
clearance rates (g) in wildtype and K14-VEGF-C mice. Quantification
of Evans blue dye concentration (h) at 24 h after dye extraction from
ear skin. **P\ 0.01 (two-tailed Student’s t test). Data are
mean ± SD. (Color figure online)
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and aged groups). Together, these results reveal a consistent
decline in lymphatic clearance during the aging process.
Decreased lymphatic clearance during aging is
not associated with a reduction of vascular leakage
Since lymph formation is in large part driven by blood
vascular capillary filtration we aimed to test if the decline
in lymphatic function found in aged mice was associated
with a reduction in vascular leakage. We measured blood
vessel perfusion and leakage in the ears of young (n = 6)
and aged (n = 5) C57BL/6 J-Tyrc-J albino mice using a
dynamic NIR imaging approach [18]. P20D800 was
injected i.v. into the tail vein and the dynamics of fluo-
rescence enhancement in the ear was compared to the
fluorescence signal in the saphenous vein of the mice
(Fig. 3a). Using this approach we found that there was no
significant difference in dye perfusion into the ear blood
vessels between young and aged mice (blood volume
fraction: young = 0.079 ± 0.012, aged = 0.093 ± 0.020;
P = 0.17; Fig. 3b). However, aged mice had a significantly
increased tissue leakage rate in the ears when compared to
young mice (tissue leakage rate: young = 0.0014
± 0.0003 min-1, aged = 0.0022 ± 0.0007 min-1; P =
0.021; Fig. 3c). After normalization of the tissue leakage
rate to the blood volume fraction the resultant vascular
leakage rate was also significantly increased in aged mice
(vascular leakage rate: young = 0.0176 ± 0.0028 min-1,
aged = 0.0244 ± 0.0066 min-1; P = 0.044; Fig. 3d).
These findings indicate that the reduced lymphatic clear-
ance rate in aged mice after intradermal injection of tracers
cannot be explained by a reduction of the steady-state
vascular leakage rate with age.
Decreased lymphatic vascular density and network
complexity during aging
We hypothesized that the decreased lymphatic clearance in
aged mice might be related to the density of lymphatic vessels
in the skin. Therefore, we performed whole mount stainings
with the lymphatic vascularmarker LYVE-1 on ears of young,
middle-aged, and aged C57BL/6C mice (Fig. 4a). Quantifi-
cation revealed that the area covered byLYVE-1 ? lymphatic
vessels (young = 0.188 ± 0.014 mm2, middle-aged =
0.166 ± 0.020 mm2, aged = 0.149 ± 0.021 mm2; P =
0.002 between young and aged; Fig. 4b) as well as the total
lymphatic vessel length per region of interest (Fig. 4c) were
decreased during aging (young = 40.0 ± 1.1 mm, middle-
aged = 37.9 ± 1.8 mm, aged = 34.8 ± 1.5 mm; P =
0.037 between young and middle-aged; P\0.001 between
young and aged; P = 0.002 between middle-aged and aged).
The average vessel diameter was not significantly changed
Fig. 2 Reduced lymphatic clearance from skin in aged mice.
a Lymphatic specific fluorescent tracer (3 lL of 3 lM P20D800)
was injected into the skin of both ears of 2 months old (young,
n = 10), 7 months old (middle-aged, n = 10), and 18 months old
(aged, n = 7) mice. Sequential imaging was performed to track the
disappearance of the fluorescent signal. Quantification of half-lives
(b) and clearance rates (c) in young, middle-aged and aged mice.
*P\ 0.05, **P\ 0.01, ***P\ 0.001 (one-way ANOVA with
Tukey’s multiple comparison test). Data are mean ± SD. (Color
figure online)
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during aging (young = 47.1 ± 3.7 lm, middle-aged =
43.8 ± 5.9 lm, aged = 42.7 ± 5.4 lm; P = 0.428 between
young andmiddle-aged; P = 0.267 between young and aged;
P = 0.903 between middle-aged and aged; Fig. 4d), whereas
the number of branch points per vessel length was decreased
with aging (young = 2.4 ± 0.4 mm-1, middle-aged = 2.0
± 0.3 mm-1, aged = 1.9 ± 0.2 mm-1; P = 0.019 between
young and middle-aged; P = 0.007 between young and aged;
P = 0.801betweenmiddle-agedandaged;Fig. 4e), indicatinga
reduction in the overall lymphatic vascular network complexity.
Discussion
In this study, we have established a method for the
quantitative in vivo measurement of lymphatic clearance
by tracking the disappearance of an injected, lymphatic-
specific NIR fluorescent tracer from the skin of mice over
time. To develop this functional assay, we adapted a
method that has been established in the clinic using
radiolabeled tracers [13]. In this procedure, a bolus of
imaging tracer is injected into the skin and a rate removal
constant k is calculated using serial imaging. For mice, a
NIR lymphatic-specific tracer that we developed previ-
ously for visualization of collecting lymphatic vessel
function was used [15]. We directly compared this tech-
nique to the established Evans Blue assay in which the
amount of residual dye after a period of time can be
calculated by extracting the dye from the tissue of sacri-
ficed mice [20]. With the NIR method, we were able to
detect a significantly increased lymphatic clearance
function in K14-VEGF-C mice [16] versus wildtype
controls with only three mice per group. By comparison,
the difference between groups with the Evans Blue tech-
nique did not reach significance with this limited number
of mice, due to an increased variability of the data points.
Interestingly, K14-VEGF-C mice demonstrated an
immediate spreading throughout the ear tissue after
intradermal injection of both P20D800 and Evans blue.
We confirmed using high-resolution lymphangiography
that the spreading of tracer indeed occurs within the
lymphatic vasculature of these mice with no apparent
leakage into the interstitium. The expansion of a func-
tional dermal lymphatic vessel network in these mice
improved the clearance of intradermally injected tracers,
most likely by increasing the available volume for
absorption of macromolecules. The improved lymphatic
function may be beneficial in K14-VEGF-C mice, as we
have previously shown that these mice have reduced ear
swelling in both acute and chronic inflammatory models
compared to wildtype controls [20, 26]. We also validated
the method by demonstrating a significant reduction of
lymphatic clearance from both ears and paws in K14-
sVEGFR-3-Fc mice [17]. These findings are in agreement
with a recently reported study testing lymphatic function
in the paws of these mice [25].
Fig. 3 Increased vascular leakage in ear skin of aged mice.
a Representative images of the ears of 2 months old (young, n = 6)
and 18 months old (aged, n = 5) C57BL/6 J-Tyrc-J albino mice at 1,
5, 10 and 15 min after tail vein injection of P20D800. Sequential
imaging was performed to calculate vascular leakage of the
fluorescent tracer. Quantification of blood volume fraction (b), tissue
leakage rate (c) and vascular leakage rate (d) in young and aged mice.
*P\ 0.05, **P\ 0.01, ***P\ 0.001 (two-tailed Student’s t test).
Data are mean ± SD. (Color figure online)
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Among the many advantages of a fluorescence-based
method are the ability to normalize the signal to a value
directly after injection, the possibility to monitor the decay
of signal over several time points allowing a curve fit to an
exponential decay model, elimination of the need to sac-
rifice the animals for dye extraction allowing longitudinal
monitoring over time, and the capability to preserve the
tissue for further analyses such as immunohistochemistry.
Recently, a method was described using fluorescently
labeled human serum albumin to track lymphatic clearance
from the paws of mice [14]. This method has the potential
advantage of monitoring the clearance of a serum protein
Fig. 4 Decreased lymphatic density and network complexity in skin
of aged mice. a Whole mount preparations of ears were stained with
anti-LYVE-1 antibody for visualization of the lymphatic network of
the ear skin in young (n = 7), middle aged (n = 8) and aged (n = 7)
mice. Images of the lymphatic network near the ear rim (yellow boxes
in upper panels) were acquired using a fluorescence stereomicroscope
(lower panels, scale bar indicates 500 lm). Quantification of LYVE-
1? area (b), total vessel length (c), average vessel diameter (d) and
number of branch points per length of lymphatic vessel (e) in young,
middle-aged and aged mice. *P\ 0.05, **P\ 0.01, ***P\ 0.001
(one-way ANOVA with Tukey’s multiple comparison test). Data are
mean ± SD. (Color figure online)
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commonly found in interstitial tissue; however, as pointed
out by the authors, the use of human albumin in rodents
may lead to an immune response that may hinder longi-
tudinal studies [14].
We applied the NIR clearance assay to evaluate the
lymphatic function in C57BL/6C mice of different age
groups. The lymphatic clearance from the skin was
decreased with aging, with significant increases of clear-
ance half-lives in mice aged from 2 months (young) to
7 months (middle-aged) and from 7 months to 18 months
(aged). As the lymphatic clearance assay measures the
removal rate of an interstitially injected tracer, it could be
affected by several factors. First, the vascular leakage from
plasma could play a role, as it is the main driving force for
the formation of lymph from interstitial fluid. The com-
position of the interstitium could affect the diffusion of
fluid (and the convective transport of the tracer) through
the tissue to reach the lymphatic vessels, and the density of
the initial lymphatic vessels in the tissue could affect the
uptake of lymph from the interstitium by changing the
surface area available for absorption. Finally, changes may
be seen in the collecting lymphatic vessel morphology and
function that transport lymph back towards the blood cir-
culatory system.
We first measured blood vascular leakage using NIR
imaging in the ear skin of young versus aged mice. The
results indicated that neither blood vascular density nor
leakage was reduced with aging. On the contrary, we found
that the vascular leakage was slightly increased in the aged
skin similar to previous reports on murine heart and brain
tissue [27, 28]. Therefore, we believe that a diminished
capillary filtration cannot explain the reduced lymphatic
clearance with aging.
We next focused our efforts to evaluate the effects of
aging on the network of initial lymphatic vessels in the
skin. Using whole mount stainings of ears for the lymphatic
marker LYVE-1 to assess the density and morphology of
initial lymphatic vessels, we found a significant reduction
in lymphatic density in the skin of aged mice compared to
young controls. These changes are similar to those reported
in blood vessels and lymphatic vessels in the photoaged
skin of humans [29, 30]. While there was no difference in
the diameter of the initial lymphatic vessels, a reduction of
branching points was found in aged mice, indicating a
reduced complexity of the network. These results indicate
that involution may be occurring in the lymphatic vessel
network of the skin during the aging process.
In conclusion, our findings reveal a decrease in lym-
phatic function in mouse skin during the aging process with
a concomitant reduction of the density and complexity of
the initial lymphatic network. Since many lymphatic-re-
lated diseases are more prevalent in aged individuals, this
decline of function may have clinical implications for a
range of conditions including autoimmune diseases,
atherosclerosis, cancer, and lymphedema.
Acknowledgments The authors thank Jeannette Scholl and Carlos
Ochoa for excellent technical assistance. This work was supported by
Swiss National Science Foundation Grants 3100A0-108207 and
31003A-130627, Advanced European Research Council Grant
LYVICAM, Oncosuisse, Krebsliga Zurich, and Leducq Transatlantic
Network of Excellence on Lymph Vessels in Obesity and Cardio-
vascular Disease (11CVD03).
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict
of interest.
Ethical approval All applicable international, national, and/or
institutional guidelines for the care and use of animals were followed.
References
1. Alitalo K (2011) The lymphatic vasculature in disease. Nat Med
17(11):1371–1380. doi:10.1038/nm.2545
2. Proulx ST, Luciani P, Dieterich L, Karaman S, Leroux JC, Det-
mar M (2013) Expansion of the lymphatic vasculature in cancer
and inflammation: new opportunities for in vivo imaging and
drug delivery. J Control Release 172(2):500–507. doi:10.1016/j.
jconrel.2013.04.027
3. Martel C, Li W, Fulp B, Platt AM, Gautier EL, Westerterp M,
Bittman R, Tall AR, Chen SH, Thomas MJ, Kreisel D, Swartz
MA, Sorci-Thomas MG, Randolph GJ (2013) Lymphatic vascu-
lature mediates macrophage reverse cholesterol transport in mice.
J Clin Invest 123(4):1571–1579. doi:10.1172/JCI63685
4. Lim HY, Thiam CH, Yeo KP, Bisoendial R, Hii CS, McGrath
KCY, Tan KW, Heather A, Alexander JSJ, Angeli V (2013)
Lymphatic vessels are essential for the removal of cholesterol
from peripheral tissues by SR-BI-mediated transport of HDL.
Cell Metab 17(5):671–684. doi:10.1016/j.cmet.2013.04.002
5. Wiig H, Schroder A, Neuhofer W, Jantsch J, Kopp C, Karlsen
TV, Boschmann M, Goss J, Bry M, Rakova N, Dahlmann A,
Brenner S, Tenstad O, Nurmi H, Mervaala E, Wagner H, Beck
FX, Muller DN, Kerjaschki D, Luft FC, Harrison DG, Alitalo K,
Titze J (2013) Immune cells control skin lymphatic electrolyte
homeostasis and blood pressure. J Clin Invest 123(7):2803–2815.
doi:10.1172/JCI60113
6. Ryan T (2004) The ageing of the blood supply and the lymphatic
drainage of the skin. Micron 35(3):161–171. doi:10.1016/j.
micron.2003.11.010
7. Mortimer PS (1995) Evaluation of lymphatic function: abnormal
lymph drainage in venous disease. Int Angiol 14(3 Suppl 1):32–35
8. Conway WC, Faries MB, Nicholl MB, Terando AM, Glass EC,
Sim M, Morton DL (2009) Age-related lymphatic dysfunction in
melanoma patients. Ann Surg Oncol 16(6):1548–1552. doi:10.
1245/s10434-009-0420-x
9. Gasheva OY, Knippa K, Nepiushchikh ZV, Muthuchamy M,
Gashev AA (2007) Age-related alterations of active pumping
mechanisms in rat thoracic duct. Microcirculation 14(8):827–839.
doi:10.1080/10739680701444065
10. Nagai T, Bridenbaugh EA, Gashev AA (2011) Aging-associated
alterations in contractility of rat mesenteric lymphatic vessels.
Microcirculation 18(6):463–473. doi:10.1111/j.1549-8719.2011.
00107.x
Angiogenesis (2015) 18:489–498 497
123
11. Akl TJ, Nagai T, Cote GL, Gashev AA (2011) Mesenteric lymph
flow in adult and aged rats. Am J Physiol Heart Circ Physiol
301(5):H1828–H1840. doi:10.1152/ajpheart.00538.2011
12. Unno N, Tanaka H, Suzuki M, Yamamoto N, Mano Y, Sano M,
Saito T, Konno H (2011) Influence of age and gender on human
lymphatic pumping pressure in the leg. Lymphology 44(3):
113–120
13. Modi S, Stanton A, Mortimer P, Levick J (2007) Clinical
assessment of human lymph flow using removal rate constants of
interstitial macromolecules: a critical review of lymphoscintig-
raphy. Lymphat Res Biol 5(3):183–202
14. Karlsen TV, McCormack E, Mujic M, Tenstad O, Wiig H (2012)
Minimally invasive quantification of lymph flow in mice and rats
by imaging depot clearance of near-infrared albumin. Am J
Physiol Heart Circ Physiol 302(2):H391–H401. doi:10.1152/
ajpheart.00842.2011
15. Proulx ST, Luciani P, Christiansen A, Karaman S, Blum KS,
Rinderknecht M, Leroux JC, Detmar M (2013) Use of a PEG-
conjugated bright near-infrared dye for functional imaging of
rerouting of tumor lymphatic drainage after sentinel lymph node
metastasis. Biomaterials 34(21):5128–5137. doi:10.1016/j.bioma
terials.2013.03.034
16. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala
H, Swartz M, Fukumura D, Jain RK, Alitalo K (1997) Hyper-
plasia of lymphatic vessels in VEGF-C transgenic mice. Science
276(5317):1423–1425
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